Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Predictive value of tissue factor bearing microparticles in cancer associated thrombosis.

Zwicker JI.

Thromb Res. 2010 Apr;125 Suppl 2:S89-91. doi: 10.1016/S0049-3848(10)70022-0. Review.

PMID:
20434015
2.

Unconventional approaches to the prevention of cancer associated thrombosis.

Zwicker JI.

Thromb Res. 2014 May;133 Suppl 2:S44-8. doi: 10.1016/S0049-3848(14)50008-4. Review.

PMID:
24862145
3.

Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.

Schoot RA, Kremer LC, van de Wetering MD, van Ommen CH.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD009160. doi: 10.1002/14651858.CD009160.pub2. Review.

PMID:
24026801
4.

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).

Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B.

Br J Haematol. 2013 Feb;160(4):530-7. doi: 10.1111/bjh.12163. Epub 2012 Dec 13.

5.

Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.

Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B.

Clin Cancer Res. 2009 Nov 15;15(22):6830-40. doi: 10.1158/1078-0432.CCR-09-0371. Epub 2009 Oct 27.

6.

Treatment of venous thromboembolism in cancer patients.

Petralia GA, Kakkar AK.

Semin Thromb Hemost. 2007 Oct;33(7):707-11. Review.

PMID:
18000799
7.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008500. doi: 10.1002/14651858.CD008500.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(8):CD008500.

8.

Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.

Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI.

Am J Med. 2014 Jan;127(1):82-6.e1. doi: 10.1016/j.amjmed.2013.09.015. Epub 2013 Oct 5.

PMID:
24384102
9.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
10.

Microparticles and cancer thrombosis in animal models.

Mege D, Mezouar S, Dignat-George F, Panicot-Dubois L, Dubois C.

Thromb Res. 2016 Apr;140 Suppl 1:S21-6. doi: 10.1016/S0049-3848(16)30094-9. Review.

PMID:
27067974
11.

Thromboprophylaxis during chemotherapy in patients with advanced cancer.

Agnelli G, Verso M.

Thromb Res. 2010 Apr;125 Suppl 2:S17-20. doi: 10.1016/S0049-3848(10)70007-4.

PMID:
20433999
12.

[Thoughts about thromboembolic events prophylaxis in cancer patients].

Pikó B, Kremer IM, Rahoty P, Bassam A, Dimák S, Kis A, Csiffári M, Rus-Gal P, Szabó Z, Veréb B, Zsilak J.

Magy Onkol. 2011 Sep;55(3):164-9. doi: MagyOnkol.2011.55.3.164. Epub 2011 Feb 21. Review. Hungarian.

13.

Prevention of deep vein thrombosis in cancer patients.

Lee AY.

Semin Thromb Hemost. 2007 Oct;33(7):699-706. Review.

PMID:
18000798
14.

Cancer and venous thrombosis: current comprehensions and future perspectives.

Lauw MN, van Doormaal FF, Middeldorp S, Buller HR.

Semin Thromb Hemost. 2013 Jul;39(5):507-14. doi: 10.1055/s-0033-1343891. Epub 2013 Apr 29. Review.

PMID:
23629821
15.

What is the effect of low-molecular weight heparin for venous thromboembolism prophylaxis compared with mechanical methods, on the occurrence of hemorrhagic and venous thromboembolic complications in patients with intracerebral hemorrhage? A critically appraised topic.

O'Carroll CB, Capampangan DJ, Aguilar MI, Bravo TP, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM.

Neurologist. 2011 Jul;17(4):232-5. doi: 10.1097/NRL.0b013e318222d6c0.

PMID:
21712672
16.

Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline.

Al-Hameed F, Al-Dorzi HM, AlMomen A, Algahtani F, AlZahrani H, AlSaleh K, AlSheef M, Owaidah T, Alhazzani W, Neumann I, Wiercioch W, Brozek J, Schünemann H, Akl EA.

Ann Saudi Med. 2015 Mar-Apr;35(2):95-106. doi: 10.5144/0256-4947.2015.95.

17.

[Cancer and venous thromboembolism].

Meyer G, Belmont L.

Rev Mal Respir. 2011 Apr;28(4):443-52. doi: 10.1016/j.rmr.2011.02.007. Epub 2011 Mar 22. Review. French.

PMID:
21549900
18.

Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.

Petersen LJ.

Cancer Treat Rev. 2009 Dec;35(8):754-64. doi: 10.1016/j.ctrv.2009.08.009. Epub 2009 Sep 16. Review.

PMID:
19762155
19.

Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials.

Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S; Meta-Embol Group.

Arthroscopy. 2014 Aug;30(8):987-96. doi: 10.1016/j.arthro.2014.03.009. Epub 2014 May 10.

PMID:
24813323
20.

Thromboprophylaxis during chemotherapy after advanced cancer.

Agnelli G, Verso M.

Thromb Res. 2007;120 Suppl 2:S128-32. Erratum in: Thromb Res. 2008;123(1):187-90.

PMID:
18023706

Supplemental Content

Support Center